Description

Letrozole 2.5 mg by Swiss Healthcare is a pharmaceutical-grade oral aromatase inhibitor (AI), originally developed for clinical use in treating estrogen-dependent breast cancer. In modern research, Letrozole is widely studied for its ability to suppress estrogen synthesis, making it a key compound in studies involving hormonal modulation, androgen optimization, and post-cycle recovery dynamics.

Letrozole works by inhibiting the aromatase enzyme, responsible for converting androgens into estrogens. This results in significantly reduced estrogen levels, which can be valuable in experimental models involving testosterone enhancement, estrogen control, or hypogonadism-related research. It is one of the most potent non-steroidal AIs available, known to reduce estrogen levels by over 95% in controlled settings.

Manufactured to strict pharmaceutical standards, each bottle contains 60 oral tablets, with 2.5 mg of Letrozole per tablet—delivering consistent, precise dosing for research-only use.

Product Details

• Active Ingredient: Letrozole

• Concentration per Tablet: 2.5 mg

• Form: Oral tablets

• Package Size: 60 tablets per bottle

Pharmacokinetics

Letrozole has a long half-life of approximately 2 days, allowing for once-daily or alternate-day dosing in research studies. It achieves near-complete suppression of circulating estrogen within 48–72 hours of administration and is highly selective for the aromatase enzyme with minimal off-target interaction.

Usage Recommendations

• Typical Research Dosage (historical reference): 0.5–2.5 mg per day, depending on study goals

• Current Use: For research and laboratory purposes only

• Administration: Oral

Disclaimer

This product is intended strictly for research and laboratory use only. It is not approved for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with hormone-sensitive conditions. Handle in accordance with applicable laws and safety standards.